Standard treatments for pancreatic cancer are often ineffective as they cannot be directly delivered to the tumor.
A promising potential new option for targeted treatment is being studied in a clinical trial intended to investigate its effect on reducing the chances of the cancer spreading and extending survival, while improving quality of life.
Introducing Trans-Arterial Micro-Perfusion (TAMP®)
TAMP therapy utilizes RenovoRx’s proprietary platform technology designed to deliver well-established chemotherapeutic agents for localized treatment of solid cancer tumors, to increase survival and improve quality of life. This drug delivery technology enables TAMP to isolate the anatomy and micro-perfuse targeted tissue with small molecule chemotherapy.
The TIGeR-PaC clinical trial is a randomized study of intra-arterial gemcitabine utilizing the TAMP procedure and is enrolling locally advanced, unresectable pancreatic cancer patients. In one clinical study gemcitabine delivered directly via the pancreatic arteries using TAMP was associated with more than half the patients living over two years.*
* Agah, Ramtin, Rosemurgy, Alexander. Safety Study of Targeted and Localized Intra-Arterial Delivery of Gemcitabine in Patients with Locally Advanced Pancreatic Adenocarcinoma, Journal of Pancreatic Cancer; Vol. 3, issue 1.
In The News
RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium
RenovoRx Continues with Strong Momentum and Reaches Milestone of 100th Patient Enrolled in its Phase III TIGeR-PaC Clinical Trial
* Individual results may vary.